Kiai Parsa, a director at Medifast Inc., has reported the acquisition of 661 shares of the company, as detailed in a recent SEC filing. This transaction, dated November 4, 2026, holds significance as it reflects Parsa's ongoing commitment to his investment in Medifast and could influence the company's strategic direction.

Background

Kiai Parsa is associated with Medifast Inc., a company that operates in the miscellaneous food preparations and kindred products sector. The company is publicly traded, although specific ticker symbols and exchanges were not listed in the filing. Recent filings indicate Parsa's active involvement in the company's stock transactions, with multiple Form 4 submissions recorded in the past months.

What the Filing Says

The SEC filing reveals that Parsa purchased the shares at an average price of $13.0255 each, with actual prices ranging from $12.87 to $13.15. Following this transaction, Parsa now owns a total of 21,089 shares of Medifast. The filing states, "Ownership of Steamboat Capital Partners II, LP (II)." This indicates that Parsa may have a pecuniary interest in the shares owned by the partnership.

Impact

This acquisition may have implications for Medifast's management and investor relations. Parsa's position as a director suggests that his investment decisions could reflect confidence in the company's future performance. Other investors may view this move as a positive signal, potentially influencing their own investment strategies.

What's Next

The filing does not specify what actions will follow this transaction. However, continued monitoring of Parsa's activities and any future filings could provide insights into his ongoing strategy regarding Medifast.